Hemicrania Continua: What to Do When Indomethacin Is Not Tolerated or Has Not Worked

Indomethacin is the established first-choice treatment for hemicrania continua, used for both acute exacerbations and prolonged prevention. When a patient cannot tolerate it, or when treatment fails to reach the expected level of pain relief, a structured next-line approach is needed.

Previous Treatment — Failure Condition

Prior therapy: Indomethacin (first-line). The required clinical goal — at least partial relief of the continuous unilateral headache pain, ideally complete pain freedom — was not achieved, or the drug could not be continued due to intolerance.

Next-Line Approach (partial overview)

The protocol for this situation includes a defined selection of alternative anti-inflammatory agents and preventive options — both pharmacological and procedural — with the specific choice guided by the patient's individual profile. The full sequencing and criteria are in the complete protocol.

Treatment Goals

The target is relief of the characteristic continuous unilateral headache. At minimum, partial pain reduction qualifies a patient as a responder; complete pain freedom defines a complete responder.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1186/s10194-017-0777-3

For the acute treatment of HC, piroxicam and celecoxib have shown good results, whilst for the prolonged treatment celecoxib, topiramate and gabapentin are good options besides indomethacin.

Gabapentin, topiramate, melatonin and OnabotA seems to be comparable in terms of effectiveness even if, considering the p-values of these comparisons (p = 0.063), a better action for gabapentin and topiramate than melatonin should be hypothesed.

Every patient was classified as a responder if he/she was accredited with, at least, a partial relief. Moreover, as to grade the different therapies better, pain-free patients were sub-classified as complete responders.

View source ↗